Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (351-360 of 531) with videos related to

Pageof 54
Sort By:
Pharmacotherapy|December 28, 1999
Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospitalC M Weingarten, M J Rybak, B E Jahns, et al.
International Journal of Antimicrobial Agents|August 16, 2011
Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureusDiixa Patel, Mashkur Husain, Celine Vidaillac, et al.
Antimicrobial Agents and Chemotherapy|July 2, 1999
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicityM J Rybak, B J Abate, S L Kang, et al.
Infectious Diseases and Therapy|November 23, 2017
Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional AnalysisKimberly C Claeys, Evan J Zasowski, Trang D Trinh, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2020
Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insightsRazieh Kebriaei, Seth A Rice, Nivedita B Singh, et al.
Pharmacotherapy|November 29, 2007
Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomesSusan L Davis, Peggy S McKinnon, Levi M Hall, et al.
The Journal of Infectious Diseases|March 30, 2013
Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureusCeline Vidaillac, Susana Gardete, Ryan Tewhey, et al.
Drug Discovery Today|October 22, 2020
Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistanceKushal Vanamala, Katyayani Tatiparti, Ketki Bhise, et al.
Open Forum Infectious Diseases|June 25, 2020
Corrigendum to: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections Treated With VancomycinEvan J Zasowski, Trang D Trinh, Safana M Atwan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2013
Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort studyKyle P Murray, Jing J Zhao, Susan L Davis, et al.
Pageof 54

Showing results (351-360 of 531) with videos related to

Sort By:
Pageof 54
Pharmacotherapy|December 28, 1999
Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospitalC M Weingarten, M J Rybak, B E Jahns, et al.
International Journal of Antimicrobial Agents|August 16, 2011
Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureusDiixa Patel, Mashkur Husain, Celine Vidaillac, et al.
Antimicrobial Agents and Chemotherapy|July 2, 1999
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicityM J Rybak, B J Abate, S L Kang, et al.
Infectious Diseases and Therapy|November 23, 2017
Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional AnalysisKimberly C Claeys, Evan J Zasowski, Trang D Trinh, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2020
Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insightsRazieh Kebriaei, Seth A Rice, Nivedita B Singh, et al.
Pharmacotherapy|November 29, 2007
Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomesSusan L Davis, Peggy S McKinnon, Levi M Hall, et al.
The Journal of Infectious Diseases|March 30, 2013
Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureusCeline Vidaillac, Susana Gardete, Ryan Tewhey, et al.
Drug Discovery Today|October 22, 2020
Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistanceKushal Vanamala, Katyayani Tatiparti, Ketki Bhise, et al.
Open Forum Infectious Diseases|June 25, 2020
Corrigendum to: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections Treated With VancomycinEvan J Zasowski, Trang D Trinh, Safana M Atwan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2013
Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort studyKyle P Murray, Jing J Zhao, Susan L Davis, et al.
Pageof 54